Literature DB >> 10385199

In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.

T Takeda1, K Yoshino, E Adachi, Y Sato, K Yamagata.   

Abstract

A synthetic analog of Shiga toxin (Stx) receptor (Synsorb Pk) was quantitatively assessed to determine whether it can protect human renal adenocarcinoma cells (ACHN cells) from the cytotoxicity of Stx1 and Stx2 by coincubation experiments. Coincubation of 100 and 20 ng of Stxl and Stx2 with 50 mg of Synsorb Pk for 1 hr at 37 C in 1 ml of Eagle's Minimum Essential Medium supplemented with 1% (v/v) non-essential amino acid and 10% (v/v) fetal calf serum protected 50% of the cells from the cytotoxic effect. Chromosorb P, an inert matrix control, did not absorb the Stxs at all. Heat-treatment (boiled for 10 min) to Synsorb Pk caused a 50% decrease in Stx2-binding activity, but did not effect the Stx1 binding. Further, Stxs bound to Synsorb Pk could be demonstrated. When 20 mg of Synsorb Pk was coincubated for 30 min at 37 C in 1 ml of phosphate-buffered saline with 1 and 10 ng or more of Stx1 or Stx2, respectively, the toxins could be detected on the surface when the bound toxins on Synsorb Pk were used as the solid phase in enzyme immunoassay. The amount of 100 ng/ml of both Stxl and Stx2 appeared to saturate 20 mg/ml of Synsorb Pk after coincubating for 30 min at 37 C. While assessing the Stxs' binding activity to Synsorb Pk, it was demonstrated that Stxl had a higher affinity to Pk trisaccharide than Stx2. These observations provide useful information on the effectiveness of Synsorb Pk to trap and eliminate free Stxs produced in the gut of patients infected by Stx-producing Escherichia coli, and to prevent the progression of hemorrhagic colitis to hemolytic uremic syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385199     DOI: 10.1111/j.1348-0421.1999.tb02413.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  9 in total

Review 1.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

2.  Shiga Toxin Type 1a (Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro.

Authors:  Courtney D Petro; Eszter Trojnar; James Sinclair; Zhi-Mei Liu; Mark Smith; Alison D O'Brien; Angela Melton-Celsa
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

3.  Shiga toxin 1 is more dependent on the P proteins of the ribosomal stalk for depurination activity than Shiga toxin 2.

Authors:  Jia-Chi Chiou; Xiao-Ping Li; Miguel Remacha; Juan P G Ballesta; Nilgun E Tumer
Journal:  Int J Biochem Cell Biol       Date:  2011-09-03       Impact factor: 5.085

4.  Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.

Authors:  J C Paton; T J Rogers; R Morona; A W Paton
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.

Authors:  Michael J Flagler; Sujit S Mahajan; Ashish A Kulkarni; Suri S Iyer; Alison A Weiss
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

6.  Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.

Authors:  Shantini D Gamage; Colleen M McGannon; Alison A Weiss
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

7.  Fighting Shigella by Blocking Its Disease-Causing Toxin.

Authors:  Diksha Haksar; Mostafa Asadpoor; Torben Heise; Jie Shi; Saskia Braber; Gert Folkerts; Lluis Ballell; Janneth Rodrigues; Roland J Pieters
Journal:  J Med Chem       Date:  2021-04-28       Impact factor: 7.446

8.  Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.

Authors:  Daniela Luz; Maria Marta Amaral; Flavia Sacerdoti; Alan Mauro Bernal; Wagner Quintilio; Ana Maria Moro; Marina Sandra Palermo; Cristina Ibarra; Roxane Maria Fontes Piazza
Journal:  Toxins (Basel)       Date:  2018-12-02       Impact factor: 4.546

9.  Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.

Authors:  Shannon J Hostetter; Amy F Helgerson; James C Paton; Adrienne W Paton; Nancy A Cornick
Journal:  BMC Res Notes       Date:  2014-06-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.